Science Magazine: “‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19 “

Data from the Moderna vaccine trial revealed that the vaccine candidate had 94.1% efficacy, a much higher percentage than previously estimated. With the vaccine’s success in multiple cohorts, there are high hopes for a method of protecting against the coronavirus. Moderna has applied for Emergency Use Authorization from the Food and Drug Association and intends to provide 20 million doses to the U.S. by the end of the year. They also aim to make the vaccine more expensive in developed countries (approximately $40) in hopes of making the vaccine cheaper and more accessible in third-world countries. To learn more, click here. To read more about vaccines, click here.